284 related articles for article (PubMed ID: 32314519)
1. Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study.
Romano M; Gravina AG; Nardone G; Federico A; Dallio M; Martorano M; Mucherino C; Romiti A; Avallone L; Granata L; Priadko K; Compare D; Tuccillo C; Romito MR; Sgambato D; Miranda A; Romano L; Loguercio C; Bazzoli F; Zagari RM
Helicobacter; 2020 Aug; 25(4):e12694. PubMed ID: 32314519
[TBL] [Abstract][Full Text] [Related]
2. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P
Digestion; 2013; 88(1):33-45. PubMed ID: 23880479
[TBL] [Abstract][Full Text] [Related]
4. Bismuth containing quadruple therapy versus tailored therapy as first-line treatments for
Cha B; Bang BW; Shin JB; Ko EJ; Ko W; Kwon KS; Shin YW; Suh YJ; Kim H
Scand J Gastroenterol; 2021 Sep; 56(9):1017-1022. PubMed ID: 34369255
[TBL] [Abstract][Full Text] [Related]
5. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
Nyssen OP; Perez-Aisa A; Rodrigo L; Castro M; Mata Romero P; Ortuño J; Barrio J; Huguet JM; Modollel I; Alcaide N; Lucendo A; Calvet X; Perona M; Gomez B; Gomez Rodriguez BJ; Varela P; Jimenez-Moreno M; Dominguez-Cajal M; Pozzati L; Burgos D; Bujanda L; Hinojosa J; Molina-Infante J; Di Maira T; Ferrer L; Fernández-Salazar L; Figuerola A; Tito L; de la Coba C; Gomez-Camarero J; Fernandez N; Caldas M; Garre A; Resina E; Puig I; O'Morain C; Megraud F; Gisbert JP
Helicobacter; 2020 Oct; 25(5):e12722. PubMed ID: 32656898
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of the traditional triple and a new bismuth-containing quadruple therapy in the first-line eradication of
Varga M; Drácz L; Kolbenheyer E; Varga F; Patai ÁV; Solymosi N; Patai Á
Orv Hetil; 2019 Aug; 160(34):1340-1345. PubMed ID: 31423829
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non-inferiority study.
Jung K; Jee SR; Lee MW; Koh M; Kim SJ; Lee J; Park MI
Helicobacter; 2024; 29(3):e13084. PubMed ID: 38717034
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of second-line regimens for
Chang YL; Tung YC; Tu YK; Yeh HZ; Yang JC; Hsu PI; Kim SE; Wu MF; Liou WS; Shiu SI
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32883715
[TBL] [Abstract][Full Text] [Related]
9. Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area.
Qiao C; Li Y; Liu J; Ji C; Qu J; Hu J; Ji R; Wan M; Lin B; Lin M; Qi Q; Zuo X; Li Y
J Gastroenterol Hepatol; 2021 Sep; 36(9):2383-2388. PubMed ID: 33691344
[TBL] [Abstract][Full Text] [Related]
10. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
Kim YI; Lee JY; Kim CG; Park B; Park JY; Choi IJ
BMC Gastroenterol; 2021 Mar; 21(1):95. PubMed ID: 33653284
[TBL] [Abstract][Full Text] [Related]
11. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
12. Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection.
Pih GY; Choi KD; Gong EJ; Na HK; Ahn JY; Lee JH; Jung KW; Kim DH; Song HJ; Lee GH; Jung HY
Helicobacter; 2021 Feb; 26(1):e12759. PubMed ID: 33113240
[TBL] [Abstract][Full Text] [Related]
13. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
Zhang D; Ke L; Ni Z; Chen Y; Zhang LH; Zhu SH; Li CJ; Shang L; Liang J; Shi YQ
Medicine (Baltimore); 2017 Aug; 96(32):e7697. PubMed ID: 28796053
[TBL] [Abstract][Full Text] [Related]
14. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
Lu B; Wang J; Li J; Liu L; Chen Y
Helicobacter; 2019 Apr; 24(2):e12566. PubMed ID: 30780194
[TBL] [Abstract][Full Text] [Related]
15. [The exposure of antibiotics on the eradication of bismuth quadruple therapy in
Nie SS; Song ZQ; Suo BJ; Xue Y; Meng LM; Zhou LY
Zhonghua Nei Ke Za Zhi; 2021 Nov; 60(11):977-981. PubMed ID: 34689518
[No Abstract] [Full Text] [Related]
16. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains.
Fiorini G; Saracino IM; Zullo A; Gatta L; Pavoni M; Vaira D
Helicobacter; 2017 Dec; 22(6):. PubMed ID: 29094477
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of three-in-one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population.
Miehlke S; Frederking D; Günther T; Glocker E; Eisele B; Andresen V; Schröder S; Morgner A
Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28833925
[TBL] [Abstract][Full Text] [Related]
18. Modified quadruple therapy or bismuth-containing quadruple therapy in the first-line treatment of Helicobacter pylori in Turkey.
Yozgat A; Kasapoğlu B; Demirci S; Coşkun Sökmen F
Rev Esp Enferm Dig; 2021 Jul; 113(7):490-493. PubMed ID: 33233910
[TBL] [Abstract][Full Text] [Related]
19. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
20. Tailored therapy guided by genotypic resistance of clarithromycin and levofloxacin detected by polymerase chain reaction in the first-line treatment of Helicobacter pylori infection.
Li CL; Zhou K; Zhang YX; Suo BJ; Tian XL; Zhang YX; Ren XL; Shi YY; Zhou LY; Song ZQ
J Dig Dis; 2024 Jan; 25(1):36-43. PubMed ID: 38323705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]